Venus Remedies stock rises on getting the prestigious antibiotic award from UNICEF

About the award from UNICEF

Venus Remedies Limited has achieved a significant milestone, securing a prestigious award for its antibiotic product, Ceftriaxone 1gm, from UNICEF in the Beta Lactam tender. This recognition builds upon their earlier achievement of receiving GMP (Good Manufacturing Practices) approval from UNICEF, further solidifying their dedication to exceptional quality standards.

UNICEF’s decision highlights Venus Remedies’ unwavering commitment to excellence in healthcare. Their Ceftriaxone 1gm product has not only met but surpassed stringent quality criteria, showcasing their dedication to producing top-tier pharmaceutical solutions.

This award signifies more than just product quality. It reinforces Venus Remedies’ role as a trusted partner in global health initiatives. The company remains committed to upholding the highest standards of quality and dedication, ensuring its products significantly contribute to the well-being of communities worldwide. Venus Remedies will continue to pursue its mission of advancing global health through innovation and excellence in the pharmaceutical industry.

Share price movement

Venus Remedies Ltd. (VENUS REMEDIES) currently trading at Rs 375.95 today, a significant increase of Rs 20.80 (5.86%) from yesterday’s closing price. The stock price displayed strong movement throughout the day, reaching a high of Rs 383.90 and a low of Rs 359.50. The average price traded was Rs 374.60. It’s important to consider that the current price sits comfortably within the 52-week range of Rs 222.00 and Rs 429.60. The upper and lower price bands, set at Rs 426.15 and Rs 284.15 respectively, indicate the potential range for the stock price to fluctuate within a single trading day.

About the company

Venus Remedies, a pharmaceutical manufacturing company, was established in 1989 and specializes in anti-biotics and oncological therapeutics. With two facilities in India and Germany, the company manufactures Oncological and Cefelosporine Injectable products. It has a presence in various markets and has entered into strategic alliances with various pharmaceutical companies to launch speciality products. Venus Remedies also conducts in-house research and development activities, focusing on formulation development, NDDS (Novel Drug Delivery System), new formulations of off-patented chemicals, and analytical and chemical research.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.